Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) posted its quarterly earnings results on Monday. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.12), Zacks reports. The firm had revenue of ($1.78) million for the quarter, compared to analysts’ expectations of $7.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 3,102.90%.

Verrica Pharmaceuticals Stock Performance

VRCA traded down $0.02 on Thursday, reaching $0.72. The stock had a trading volume of 163,354 shares, compared to its average volume of 453,404. The business’s 50-day moving average price is $1.64 and its two-hundred day moving average price is $5.14. The company has a market cap of $30.79 million, a P/E ratio of -0.41 and a beta of 1.45. Verrica Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $11.41. The company has a current ratio of 2.36, a quick ratio of 2.23 and a debt-to-equity ratio of 29.58.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on VRCA shares. TD Cowen decreased their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday, October 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $11.00 to $2.00 in a research note on Tuesday. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Finally, HC Wainwright downgraded Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Verrica Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $9.60.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.